Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management
- PMID: 2898972
- PMCID: PMC1268024
Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management
Abstract
The symptoms and clinical management of alcohol, barbiturate and benzodiazepine withdrawal syndromes are discussed in this article. People who suffer alcohol withdrawal should be admitted to hospital if they have medical or surgical complications or severe symptoms; supportive care and pharmacotherapy, especially diazepam loading, are the essential components of treatment. Barbiturate withdrawal requires pharmacotherapy and admission to hospital for patients who have taken more than 0.4 g/d of secobarbital or an equivalent amount of another barbiturate for 90 days or longer, or 0.6 g/d or an equivalent dose for 30 days or longer, or who have had withdrawal seizures or delirium; phenobarbital loading is recommended. Regular benzodiazepine therapy that has lasted at least 3 months should be gradually stopped. Short-acting agents should be replaced with long-acting ones, such as diazepam, to avoid withdrawal symptoms. Most of these patients can be managed on an outpatient basis.
Similar articles
-
Treating alcohol, barbiturate, and benzodiazepine withdrawal.Ration Drug Ther. 1986 Feb;20(2):1-9. Ration Drug Ther. 1986. PMID: 2874590 No abstract available.
-
Treatment of the barbiturate abstinence syndrome.Med J Aust. 1986 Nov 3;145(9):456-8. Med J Aust. 1986. PMID: 3773832
-
Benzodiazepine withdrawal syndrome: a literature review and evaluation.Am J Drug Alcohol Abuse. 1982;9(1):19-33. doi: 10.3109/00952998209002608. Am J Drug Alcohol Abuse. 1982. PMID: 6133446 Review.
-
Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine.Alcohol Clin Exp Res. 1999 Oct;23(10):1596-604. Alcohol Clin Exp Res. 1999. PMID: 10549990 Clinical Trial.
-
Management of alcohol withdrawal.Am J Health Syst Pharm. 1995 Apr 1;52(7):697-709. doi: 10.1093/ajhp/52.7.697. Am J Health Syst Pharm. 1995. PMID: 7627738 Review.
Cited by
-
The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice.Int J Mol Sci. 2019 May 9;20(9):2288. doi: 10.3390/ijms20092288. Int J Mol Sci. 2019. PMID: 31075831 Free PMC article. Review.
-
Giant cell arteritis (temporal arteritis) affecting the breast: report of two cases and review of published reports.Ann Rheum Dis. 1990 Dec;49(12):1001-4. doi: 10.1136/ard.49.12.1001. Ann Rheum Dis. 1990. PMID: 2270958 Free PMC article. Review.
-
Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure.Eur J Clin Pharmacol. 2022 Nov;78(11):1833-1841. doi: 10.1007/s00228-022-03388-x. Epub 2022 Sep 17. Eur J Clin Pharmacol. 2022. PMID: 36114834 Free PMC article.
-
Hyperalgesia after a Drinking Episode in Young Adult Binge Drinkers: A Cross-Sectional Study.Alcohol Alcohol. 2020 Oct 20;55(6):608-615. doi: 10.1093/alcalc/agaa035. Alcohol Alcohol. 2020. PMID: 32476005 Free PMC article.
-
Risk factors for delirium tremens development.J Gen Intern Med. 1996 Jul;11(7):410-4. doi: 10.1007/BF02600188. J Gen Intern Med. 1996. PMID: 8842933
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources